Also found in: Medical.
ESRDEnd-Stage Renal Disease
ESRDEngineering Software Research and Development, Inc. (St. Louis, MO)
ESRDExperimental Systems and Research Department (Stanford University; California)
ESRDEmergency Services Routing Digits
ESRDEquipment Shipment Ready Date
ESRDExecutive Search Research Directory (eBook)
ESRDElectron Spin Resonance Data
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Remigio, M.Phil., from the University of Maryland School of Public Health in College Park, and colleagues examined the correlation between EHEs and the risk of hospital admission or mortality among patients with ESRD. Data were included for 7,445 patients with ESRD, among whom 2,953 deaths and 44,941 hospital admissions were recorded.
We support the add-on payment that is included in the End-Stage Renal Disease (ESRD) Prospective Payment System proposed rule released by the Centers for Medicare & Medicaid Services.
Patients with ESRD who do not adhere to at least one aspect of care range from 28% to 81% (Kugler, Maedling, & Russell, 2011; Forni Ogna et al., 2013; Wang, Alfieri, Ramakrishnan, Braunhofer, & Newsome, 2014).
Patients diagnosed with ESRD may choose between two primary types of dialysis: hemodialysis and peritoneal dialysis (PD).
The care of a child with ESRD is fraught with challenges for the parent, the caregiver as well as the healthcare system.
As CKD progresses and kidney function declines, ESRD ensues and dialysis or a kidney transplant is needed for survival.
In a developing country such as Egypt, with limited diagnostic resources, end-stage renal disease (ESRD) is probably the "tip of the iceberg," where patients are diagnosed with renal disease when they have already reached the end-stage renal failure [2].
It is also evident that there is little or nothing known about the proportion of people living with ESRD or requiring RRT in Rwanda.
With adequate treatment, progression to ESRD can be avoided in most patients with focal/crescentic/mixed histology and there are currently no data suggesting that different therapeutic approaches should be used for these groups.
A search of published literature (PubMed and EMBASE) from 2000 to present using the search terms, nivolumab/kidney/renal/dialysis, identified only two cases of metastatic RCC and one case of metastatic melanoma and ESRD on dialysis which received nivolumab [4-6].
The histological classification of patients with ANCA-GN into 4 groups, focal ([greater than or equal to] 50% normal glomeruli), crescentic ([greater than or equal to] 50% cellular crescents), mixed (<50% normal, <50% crescentic, and <50% globally sclerotic glomeruli), and sclerotic ([greater than or equal to] 50% globally sclerotic glomeruli), is useful for stratifying patients according to the risk of progression to ESRD [7, 20, 28-31].